Actively Recruiting
Study of Semaglutide Effects on Brain Blood Flow and Barrier in Adults with Type-2 Diabetes
Led by University of Washington · Updated on 2024-06-05
50
Participants Needed
1
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of semaglutide on intracranial blood flow and blood-brain barrier permeability in people with type-2 diabetes. This randomized, double-blind, placebo-controlled study aims to understand how semaglutide, an FDA-approved medication, may improve brain blood flow and reduce stroke risk in patients with diabetes. Preliminary data suggest that type-2 diabetes reduces brain arterial branches, indicating poorer blood flow, and semaglutide has shown stroke reduction benefits in this population. Participants will be randomly assigned to receive either semaglutide or a matching placebo for one year. Semaglutide is administered via a weekly auto-injector with a dose escalation starting at 0.25 mg, increasing to a target dose of 1 mg per week over 52 weeks. A diabetes care specialist will manage blood sugar levels to maintain HbA1C below 7.5% for both treatment groups to isolate semaglutides effects on cerebral blood flow and blood-brain barrier function. During the study, participants will undergo magnetic resonance imaging at the beginning and after one year to measure intracranial blood flow and blood-brain barrier permeability. Additional assessments will include inflammatory markers. The study will monitor participants health and glucose control throughout the year, with the primary outcomes focusing on brain circulation and barrier function after about 12 months of treatment.
CONDITIONS
Brief Title
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
Research Team
F
Francis Kim, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here